Novo Holdings Corvus Pharmaceuticals, Inc. Transaction History

Novo Holdings

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.86 - $4.77 $2.43 Million - $4.04 Million	-847,906 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.56 - $4.86 $1.93 Million - $2.63 Million	-541,592 Reduced 38.98%	847,906 $3.02 Million
Q3 2020 Nov 16, 2020	SELL	$2.6 - $5.37 $4 Million - $8.26 Million	-1,538,062 Reduced 52.54%	1,389,498 $5.57 Million
Q3 2019 Nov 14, 2019	SELL	$3.01 - $6.5 $4.49 Million - $9.7 Million	-1,492,956 Reduced 33.77%	2,927,560 $8.81 Million
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $8.8 Million - $13.6 Million	1,176,470 Added 36.27%	4,420,516 $51 Million
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $36.7 Million - $55.9 Million	3,244,046	3,244,046 $51.7 Million

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.